Download PDF
Hamostaseologie 1987; 07(06): 166-171
DOI: 10.1055/s-0038-1660549
Originalarbeit
Schattauer GmbH

Plasma-Präkallikrein

M. J. Gallimore
1   Channel Diagnostics, Walmer, Kent, England
› Author Affiliations
Further Information

Publication History

Publication Date:
25 June 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Einfache Untersuchungsmethoden für die Bestimmung der Spiegel des Plasma-Präkallikreins und anderer Komponenten der plasmatischen Abwehrsysteme sind jetzt verfügbar. Obwohl diese Tests bisher nicht voll in der Klinik verwendet wurden, so erhielt man doch eine Menge nützlicher Informationen mit Hilfe dieser Tests. Zahlreiche Laboratorien in Europa verwenden bereits diese Tests, um Patienten während Intensivbetreuung zu beobachten, und verwenden die Ergebnisse für die Entwicklung neuer Therapien. Weitere Zustände, in denen die Analyse der Komponenten dieser Systeme von Vorteil sein könnten, schließen die Organtransplantation, Lebererkrankungen, Nierenerkrankungen, die rheumatoide Arthritis, allergische Erkrankungen, Thrombosen, Hypertonie und koronare Herzerkrankung ein.

 

  • LITERATUR

  • 1 Aasen A O. The proenzyme functional inhibition index. A new parameter for evaluation of the severely injured and septic patient. Acta Chir Scand 1985; Suppl 522: 211-9.
    PubMedGoogle Scholar
  • 2 Aasen A O, Smith-Erichsen N, Gallimore M J, Amundsen E. Studies on components of the plasma kallikrein-kinin system in plasma samples from normal individuals and patients with septic shock. Adv Shock Res 1980; 04: 1-10.
    PubMedGoogle Scholar
  • 3 Aasen A O, Kierulf P, Ruud T E, Godai H C, Aune S. Studies on pathological proteolysis in patients with acute pancreatitis. A preliminary report. Acta Chir Scand 1982; Suppl 509: 83-8.
    PubMedGoogle Scholar
  • 4 Amundsen E, Gallimore M J, Aasen A O, Larsbraaten M, Lyngaas K. Activation of human plasma prekallikrein : influence of activators, activation time and temperature and inhibitors. Thromb Res 1978; 13: 625-36.
    CrossrefPubMedGoogle Scholar
  • 5 Amundsen E, Aasen A O, Gallimore M J, Larsbraaten M, Lyngaas K, Engesett A. Plasma prekallikrein activities and Cl-esterase inhibitor levels in plasma samples from cancer patients and healthy individuals. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson J F, Cepelak V, Samama M M, Desnoyers P C. (eds). Edinburgh: Churchill Livingstone; 1979: 406-10.
    Google Scholar
  • 6 Abildgaard U. A review of antithrombin III. In: The Physiological Inhibitors of Coagulation and Fibrinolysis. Collen D, Wiman B, Verstraete M. (eds). Amsterdam: Elsevier/North Holland Biomedical Press; 1979: 12-29.
    Google Scholar
  • 7 Bagdasarian A, Lahiri B, Talamo R G, Wong P, Colman R W. Immunochemical studies of plasma kallikrein. J Clin Invest 1974; 54: 1444-50.
    CrossrefPubMedGoogle Scholar
  • 8 Beatty K, Bieth J, Travis J. Kinetics of association of serine proteinases with native and oxidised alpha-l-proteinase inhibitor and alpha-l-antichymotrypsin. J Biol Chem 1980; 255: 3991-7.
    PubMedGoogle Scholar
  • 9 Bouma B N, Miles L A, Beretta G, Griffin J H. Human plasma prekallikrein. Studies of its activation by activated factor XII and its inactivation by diisopropyl phosphofluoridate. Biochemistry 1980; 19: 1151-60.
    CrossrefPubMedGoogle Scholar
  • 10 Bruhn H D, Bruck M, Albert J P. Plasma prekallikrein in hypertension. Acta Chir Scand 1982; Suppl 509: 133-5.
    PubMedGoogle Scholar
  • 11 Colman R W, Mason J W, Sherry S. The kallikreinogen-kallikrein system of human plasma. Assay of components and observation in disease states. Ann Int Med 1969; 71: 763-72.
    CrossrefPubMedGoogle Scholar
  • 12 Colman R W, Mattier L, Sherry S. Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest 1969; 48: 11-22.
    CrossrefPubMedGoogle Scholar
  • 13 Colman R W, Bagdasarian A, Talama R C, Scott C F, Seavey M, Guinaraes J A, Pierce J B, Kaplan A P. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975; 56: 1650-62.
    CrossrefPubMedGoogle Scholar
  • 14 Colman R W, Wong P Y. Participation of Hageman Factor pathways in human disease states. Thromb Haemostas 1977; 38: 751-75.
    PubMedGoogle Scholar
  • 15 Cullman W, Kovary P M, Muller N, Dick W. Complement, coagulation and fibrinolytic parameters in hereditary angioedema (HAE). Clin Exp Immunol 1982; 49: 618-22.
    PubMedGoogle Scholar
  • 16 Egberg N, Gallimore M J. Studies on Hageman factor, plasma prekallikrein, kallikrein like activity and kallikrein inhibition in plasma samples from normal subjects and clinical material. In: Kinins III Adv Exp Med Biol. Fritz H, Back N, Dietze G, Haberland G L. (eds). New York: Plenum; 1983: 109-17.
    Google Scholar
  • 17 Egberg N, Gallimore M J, Green K, Jacobsson J, Vesterqvist O, Wiman B. Effects of plasma kallikrein and bradykinin infusions into pigs on plasma fibrinolytic variables and urinary excretion of thromboxane and prostocycline metabolites. (in press).
    PubMedGoogle Scholar
  • 18 Friberger P, Gallimore M J. Description and evaluation of a new chromogenic substrate assay kit for the determination of prekallikrein in human plasma. In: Kinins I V, Part B, Greenbaum L M, Margolius H S. (eds). New York: Plenum; 1986: 543-8.
    Google Scholar
  • 19 Führer G, Gallimore M J, Heller W, Hoffmeister H-E. Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass. In: Kinins I V, Greenbaum L M, Margolius H S. (eds). New York: Plenum; (in press).
    Google Scholar
  • 20 Führer G, Heller W, Hoffmeister H-E. Effect of high and low molecular weight heparin preparations on chromogenic substrate assays for components of the kallikrein-kinin system. In: Kinins I V, Greenbaum L M, Margolius H S. (eds). New York: Plenum; (in press).
    Google Scholar
  • 21 Gallimore M J, Fareid E, Stormorken H. The purification of a human plasma kallikrein with weak plasminogen activator activity. Thromb Res 1978; 12: 409-20.
    CrossrefPubMedGoogle Scholar
  • 22 Gallimore M J, Amundsen E, Larsbraaten M, Lyngaas K, Fareid E. Studies on plasma kallikrein using chromogenic peptide substrate assays. Thromb Res 1979; 16: 695-703.
    CrossrefPubMedGoogle Scholar
  • 23 Gallimore M J, Ford C H J, Howell A, Newman C E. Further studies on components of the plasma kallikrein system in plasma samples from cancer patients and normal individuals. In: Progress in Fibrinolysis. Davidson J F, Nilsson I M, Astedt B. (eds). Edinburgh: Churchill Livingstone; 1981: 256-8.
    Google Scholar
  • 24 Gallimore M J, Friberger P. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein like activity in human plasma. Thromb Res 1982; 25: 293-8.
    CrossrefPubMedGoogle Scholar
  • 25 Gallimore M J, Milford AWard. Studies on components of the plasma kallikrein and complement systems in plasma and serum sample from normal individuals and patients with hereditary angioedema. In: Kinins III. Adv Exp Med Biol. Fritz H, Back N, Dietze G, Haberland G L. (eds). New York: Plenum; 1983: 1099-107.
    Google Scholar
  • 26 Harpel P C. Human plasma alpha 2 macroglobulin. An inhibitor of plasma kallikrein. J Exp Med 1970; 132: 329-37.
    CrossrefPubMedGoogle Scholar
  • 27 Harpel P C. Cl inactivator inhibition by plasmin. J Clin Invest 1970; 49: 568-76.
    CrossrefPubMedGoogle Scholar
  • 28 Hathaway W E, Belhanson L P, Hathaway H S. Evidence for a new thromboplastin factor: case report, coagulation studies and physiochemical studies. Blood 1965; 26: 521-8.
    PubMedGoogle Scholar
  • 29 Heber H, Geiger R, Heimburger N. Human plasma kallikrein. Purification, enzyme characterisation and quantitative determination in plasma. Hoppe-Seylers Z Physiol Chem 1978; 359: 649-69.
    PubMedGoogle Scholar
  • 30 Heller E, Führer G, Hoberg S, Hoffmeister H-E, Philapitsch A. Effect of elevated Clesterase inhibitor levels on elastase release in vitro. A proposed model for shock. (in press).
    PubMedGoogle Scholar
  • 31 Hojima Y, Tankersley D L, Miller-Andersson M, Pierce J V, Pisano J J. Enzymatic properties of human Hageman factor fragment with plasma prekallikrein and synthetic substrates. Thromb Res 1980; 18: 417-30.
    CrossrefPubMedGoogle Scholar
  • 32 Ichinose A, Fujikawa K, Suyama T. The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261: 3486-9.
    PubMedGoogle Scholar
  • 33 Kierulf P, Aasen A O, Aune S, Godai H C, Ruud T E, Vaage J. Chromogenic peptide substrates in patients with multiple trauma. Acta Chir Scand 1982; Suppl 509: 69-72.
    PubMedGoogle Scholar
  • 34 KabiVitrum A B. Stockholm, Sweden. COA-SET Prekallikrein Kit..
    PubMedGoogle Scholar
  • 35 Kluft C. Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein. J Lab Clin Med 1978; 91: 83-96.
    PubMedGoogle Scholar
  • 36 Lacombe N J. Deficit constitutional en un nouveau facteur de la coagulation intervenant au niveau de contact. Le facteur »Flaujeac«. C R Acad Sci (D) 1975; 280: 1039-41.
    PubMedGoogle Scholar
  • 37 Lasson A. Acute pancreatitis in man. Scand J Gastro 1984; Suppl 99: 1-57.
    PubMedGoogle Scholar
  • 38 Mandle R J, Colman R W, Kaplan A P. Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proc Natl Acad Sci 1976; 11: 4179-85.
    PubMedGoogle Scholar
  • 39 McConnell D J, Mason B. The isolation of human plasma prekallikrein. Br J Pharmacol 1970; 38: 490-502.
    CrossrefPubMedGoogle Scholar
  • 40 Mullertz S. The primary plasmin inhibitor, ±2-plasmin inhibitor or ±2-antiplasmin : a review. In: The Physiological Inhibitors of Coagulation and Fibrinolysis. Collen D, Wiman B, Verstraete M. (eds). Amsterdam: Elsevier/North Holland Biomedical Press; 1979: 87-102.
    Google Scholar
  • 41 Pisaro J J. Chemistry and biology of the kallikrein-kinin system. In: Proteases and Biological Control. Cold Spring Harbour. Conference on Cell Proliferation 1975; 02: 199-207.
    PubMedGoogle Scholar
  • 42 Ratnoff O D, Colopy J E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 601-13.
    PubMedGoogle Scholar
  • 43 Ratnoff O D, Naff G B. The conversion of Cls to Cl esterase by plasmin and trypsin. J Exp Med 1967; 125: 337-45.
    CrossrefPubMedGoogle Scholar
  • 44 Ratnoff O D, Pensky J, Ogston D, Naff G B. The inhibition of plasmin, plasma kallikrein, plasma permeability factor and the C’lr subcomponent of the first component of complement by serum C’l esterase inhibitor. J Exp Med 1969; 129: 315-24.
    CrossrefPubMedGoogle Scholar
  • 45 Revak S D, Cochrane C G, Griffin J H. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein or high molecular weight kininogen. J Clin Invest 1977; 59: 1167-75.
    CrossrefPubMedGoogle Scholar
  • 46 Revak S D, Cochrane C G, Griffin J H. Multiple forms of active Hageman factor (coagulation Factor XII) produced during contact activation. Fed Proc 1977; 36: 329-38.
    PubMedGoogle Scholar
  • 47 Saito H, Ratnof W, Waldman A, Abraham J P. Fitzgerald trait. Deficiency of a hitherto unrecognised agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinins and the property of diluted plasma enhancing vascular permeability (PF/dil). J Clin Invest 1975; 55: 1082-9.
    PubMedGoogle Scholar
  • 48 Saito H, Goodnough L T, Soria J, Soria C, Aznar J, Espana F. Heterogeneity of human prekallikrein deficiency (Fletcher trait). Evidence that 5 of 18 cases are positive for cross-reacting material. N Engl J Med 1981; 305: 910-4.
    CrossrefPubMedGoogle Scholar
  • 49 Saugstad O D, Harvie A, Langslet A. Activation of the kallikrein-kinin system in premature infants with respiratory distress syndrome (RDS). Acta Chir Scand 1982; Suppl 509: 79-80.
    PubMedGoogle Scholar
  • 50 Schrader J, Gallimore M J, Eisenhauer T, Isemer F E, Schoel G, Bruggeman M, Scheler F. Parameters of the kallikreinkinin, coagulation and fibrinolytic systems as early indicators of kidney transplant rejection. Nephron. (in press).
    PubMedGoogle Scholar
  • 51 Schreiber A D, Kaplan A P, Austen K F. Inhibition by Cl INH of Hageman factor fragment activation of coagulation, fibrinolysis and kinin generation. J Clin Invest 1974; 52: 1402-9.
    PubMedGoogle Scholar
  • 52 Smith-Erichsen N, Aasen A O, Amundsen E. Treatment of sepsis in the surgical patient evaluated by means of chromogenic peptide substrate assays. Acta Chir Scand 1982; Suppl 509: 33-8.
    PubMedGoogle Scholar
  • 53 Stormorken H, Baklund A, Gallimore M J, Ritland S. Chromogenic substrate assay of plasma prekallikrein. Heaemostasis 1978; 07: 69-75.
    PubMedGoogle Scholar
  • 54 Thompson R, Mandle Jr R, Kaplan A P. Association of Factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60: 1376-84.
    CrossrefPubMedGoogle Scholar
  • 55 Van Vliet A C M, van Vliet H H D M, Dzolijic-Danilovic G, Wilson J H P. Plasma prekallikrein and endotoxemia in liver cirrhosis. Thromb Haemostas 1981; 45: 65-9.
    PubMedGoogle Scholar
  • 56 Velasco F, Torres A, Guerrero A, Andres P, Guerro R, Aljama P, Alvarez F. Behavior of the contact phase of blood coagulation in the adult respiratory distress syndrome (ARDS). Thromb Haemostas 1986; 55: 357-60.
    PubMedGoogle Scholar
  • 57 Vennerod A H, Laake K, Solberg A K, Stromland S. Inactivation and binding of human plasma kallikrein by antithrombin III and heparin. Thromb Res 1976; 09: 457-66.
    CrossrefPubMedGoogle Scholar
  • 58 Walker I D, Gallimore M J, Imrie C W, Davidson J F. The coagulation, fibrinolytic and plasma kallikrein systems in acute pancreatitis. In: Progress in Fibrinolysis. Davidson J F, Nilssson I M, Astedt B. (eds). Edinburgh: Churchill Livingstone; 1981: 291-3.
    Google Scholar
  • 59 Ward P N. A plasmin split fragment of C3 as a new chemotactic factor. J Exp Med 1967; 126: 189-93.
    CrossrefPubMedGoogle Scholar
  • 60 Werk W. Plasma kallikrein activities, FDP and Cl-esterase inhibitor levels in breast cancer patients. In: Progress in Fibrinolysis. Davidson J F, Nilsson I M, Astedt B. (eds). Edinburgh: Churchill Livingstone; 1981: 259-63.
    Google Scholar
  • 61 Wuepper K D. Biochemistry and biology of components of the plasma kinin forming system. In: Inflammation: Mechanisms and Control. Lepow I H, Ward P A. New York: Academic Press; 1972: 93-117.
    Google Scholar
  • 62 Wuepper K D. Prekallikrein deficiency in man. J Exp Med 1973; 138: 1345-55 63.
    CrossrefPubMedGoogle Scholar